Evaluation of Vitamin A and E Deficiency With Severity of SARS-COV-2 Disease: A Case-Control Study

COVID-19 Clinical Trial

Official title:

Correlation Between Vitamin A and E Deficiency With Severity of SARS-COV2 Disease.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05946499
• Other study ID #: Vitamin A and E in COVID-19
• Status: Completed
• Start date: September 1, 2021
• Est. completion date: May 30, 2022

Study information

• Verified date: August 2023
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Coronavirus disease 2019 (COVID-19) is a novel infectious disease that has been spreading worldwide Coronaviridae study group of the International Committee on taxonomy of viruses (2020). The clinical manifestation of COVID-19 can range from asymptomatic infection to critical illness with severe pneumonia, respiratory failure, and death.

Vitamin A is of special interest in the field of infectious diseases, especially for pulmonary infections. It is crucial for the development of normal lung tissue and tissue repair after injury due to infection. Therefore, it may play a role in recovery after severe COVID-19 pneumonia. Vitamin A has immune regulatory functions and positively affects both the innate and adaptive immune cell response.

The anti-oxidant Vitamin E, and trace element selenium, are major components of anti-oxidant defense. Epidemiological studies demonstrate that deficiencies in, either of these nutrients, alters immune responses and viral pathogenicity.

Data concerning vitamin A and E plasma levels in COVID-19 patients are lacking. Therefore, this study aims at characterizing vitamin A and E plasma levels in COVID-19 and analyzing the association of plasma levels with disease severity and outcome.

Description:

The aim of the current study is to evaluate the relation of plasma level of Vitamin A and E and their correlation with severity of SARS-COV2 disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: May 30, 2022
• Est. primary completion date: April 30, 2022
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• COVID-19 positive patients by PCR (polymerase chain reaction) test

• Patients aging 18 to 75 years

Exclusion Criteria:

• Patients with known immunodeficiency - Patients with known lung diseases

Related Conditions & MeSH terms

• COVID-19

Locations

Country	Name	City	State
Egypt	balsam Sherif Fahmy	Cairo	None Selected

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlating between vitamin A and E deficiency and severity of SARS-COV2	Evaluation of vitamin A and E deficiency with COVID-19 disease severity	From September 2021 to November 2022